Title : Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor.

Pub. Date : 2015 Nov

PMID : 26497877






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 In summary, pilaralisib or voxtalisib, in combination with letrozole, was associated with an acceptable safety profile and limited efficacy in endocrine therapy-resistant HR+ , HER2-negative metastatic breast cancer. XL765 erb-b2 receptor tyrosine kinase 2 Homo sapiens